Main content area

Identification of a point mutation PMLS214L-RARα that alters PML body organization, dynamics and SUMOylation

Zhao, Shanshan, Shi, Peng, Zhong, Qihang, Shao, Shipeng, Huang, Yuxing, Sun, Yujie, Wu, Congying, Zhu, Hong-Hu
Biochemical and biophysical research communications 2019 v.511 no.3 pp. 518-523
arsenic oxide, drug resistance, drug therapy, fluorescence recovery after photobleaching, leukemia, moieties, mutants, oncogene proteins, patients, point mutation, retinoic acid, retrospective studies, sumoylation
Genetic mutations on PML-RARα in acute promyelocytic leukemia (APL) are reported to associate with arsenic trioxide (ATO) or all-trans retinoic acid (ATRA) resistance. Here we performed a retrospective analysis of APL patients and identified that the patient with S214L mutation on the PML moiety of PML-RARα showed resistance to both ATO and ATRA. Super-resolution microcopy was used to examine the structural response of PML bodies in wild-type or the S214L mutant cells upon drug treatment. Different protein density and fluidity were identified with the S214L mutant PML bodies by single particle quantification and FRAP analysis. We discovered that altered SUMOylation and ubiquitination might contribute to the drug resistance. Taken together, we have revealed that the S214L mutation on PML-RARα disrupted the organization of PML body and dynamics changes, perturbing structural responses to ATRA and subsequent oncoprotein degradation. Our findings shed new light on the structural alterations of PML bodies and mechanisms of APL drug resistance.